Gemcitabine and vinorelbine treatment in cutaneous T‐cell lymphoma in four patients
- 13 December 2014
- journal article
- case report
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 56 (4) , 294-297
Abstract
Treatment options for advanced stage cutaneous T‐cell lymphoma (CTCL) are limited by the their efficacy and side‐effects profile. Gemcitabine, a pyrimidine analogue, has been reported to be efficacious in CTCL. Most of the studies published used gemcitabine as a single agent in treating advanced CTCL. Our small case series demonstrated that a combination of gemcitabine and vinorelbine induced partial remission in all four patients with refractory or advanced CTCL, although the effects were not sustained for a long duration (2–6 months). Two patients had neutropenia and one had acute hepatitis, requiring discontinuation of treatment.Keywords
This publication has 14 references indexed in Scilit:
- Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabineAnnals of Hematology, 2014
- Novel Therapeutic Strategies for Cutaneous T-Cell Lymphoma in Advanced StagesSeminars in Hematology, 2014
- Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung CancerClinical Medicine Insights: Oncology, 2011
- Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcomeAnnals of Oncology, 2009
- Low-Dose Gemcitabine Efficacious in Three Patients With Tumor-Stage Mycosis FungoidesClinical Lymphoma Myeloma and Leukemia, 2009
- Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 casesBritish Journal of Dermatology, 2009
- A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphomaCancer, 2008
- Phase II Evaluation of Gemcitabine Monotherapy for Cutaneous T-Cell LymphomaClinical Lymphoma Myeloma and Leukemia, 2006
- Gemcitabine as frontline treatment for cutaneous T‐cell lymphomaCancer, 2005
- Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T‐cell lymphomaCancer, 2003